TITLE

VAISTAI NUO MIKROSKOPINI#x0172; GRYB#x0172;. II DALIS. VAISTIN#x0116;S MED#x017D;IAGOS IR PREPARATAI NUO GRYB#x0172;. LITERAT#x016A;ROS AP#x017D;VALGA

AUTHOR(S)
Matusevičius, Algimantas; Ivaškienė, Marija; špakauskas, Vytautas
PUB. DATE
December 2008
SOURCE
Veterinarija ir Zootechnika;2008, Vol. 44 Issue 66, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The incidence of fungal infections have tendency to increase worldwide. The need for new antifungal agents has arisen largely through the increase in numbers of fungal infections. Relatively few agents were available for treatment of mycoses, e.g. amphotericin B, flucytosine, griseofulvine and few azoles (ketoconazole, enilconazole). The knowledge of fungal cell structure, function and metabolism gave the opportunity to synthesize new agents. The search for new, potent and broadly active antimycotics, new targets in fungal cell, modification of currently known agents was of a big interest during the past decades. This lead to development of novel antifungals belonging to wide range of structural classes, selectively acting on novel targets with fewer side effects to animals. Recently, there are more than one hundred antimycotic agents that possess fungicidal or fungistatic activity. Modern antimycotics are active chemical compounds, missaplication of which may be harmful to an animal. In our previous review the fungal cell structure, function and targets for antifungal agents were described. This review includes the mechanism of action, spectra of activity, administration of antifungals in current use in veterinary medicine, efficacy or toxicity of antifungal therapy.
ACCESSION #
36133195

 

Related Articles

  • The Role of Echinocandins in the Treatment of Invasive Candidiasis. Pappas, Peter C. // Japanese Journal of Medical Mycology;2008 Supplement 1, Vol. 49, p71 

    The article discusses the vital role of antifungal agent echinocandins in treating invasive candidiasis (IC), a fungal disease. Studies found that echinocandins are more effective and safe in the treatment of IC where 70 to 75% of patients were cured than other treatments, including amphotericin...

  • Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles. De la Serna, Javier; Jarque, Isidro; López-Jiménez, Javier; Fernández-Navarro, Jose María; Gómez, Valle; Jurado, Manuel; Pascual, Adriana; Serrano, Josefina; Romero, Mónica; Vallejo, Carlos // Revista Española de Quimioterapia;mar2013, Vol. 26 Issue 1, p64 

    There are concerns of a reduced effect of liposomal amphotericin B (L-AmB) given sequentially after mold-active azoles due to a possible antagonism in their antifungal mechanism. To investigate this possible effect in the clinic, we retrospectively studied 182 high risk hematologic patients with...

  • NOVEL DRUG DELIVERY SYSTEMS FOR ANTIFUNGAL THERAPY. Khatry, Sadhna; Shastri, Nalini; Sadanandam, M. // International Journal of Pharmacy & Pharmaceutical Sciences;Oct2010, Vol. 2 Issue 4, p6 

    The number of fungi causing systemic disease is growing and the number of systemic diseases caused by fungi is increasing. The currently available antifungal agents for the treatment of systemic mycoses include polyene antibiotics (Amphotericin B), fluoropyrimidine (Flu cytosine), Nystatin and...

  • Antifúngicos en el tratamiento de las infecciones sistémicas: importancia del mecanismo de acción, espectro de actividad y resistencias.  // Revista Española de Quimioterapia;Dec2010, Vol. 23 Issue 4, p169 

    No abstract available.

  • Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Kleinberg, M. // Medical Mycology;Feb2005 Supplement 1, Vol. 43, p289 

    Aspergillosis is a potentially lethal infection of immunocompromised patients. Until 10 years ago, antifungal therapy was largely limited to amphotericin B deoxycholate. Perceived poor response rates and inherent toxicities with amphotericin B deoxycholate were a major stimulus for the...

  • Application of caspofungin in China compared with amphotericin B and fluconazole. Chunyu Zhang; Jiaoying Cheng; Yan Jiang; Junyang Liu // Therapeutics & Clinical Risk Management;2014, Vol. 10, p737 

    Fungal infection has increased in the past 2 decades in China. There are three classes of antifungal drugs, polyenes, azoles, and echinocandins, that are applied frequently in China. Caspofungin, which disrupts the fungal cell wall glucan formation through inhibiting the enzyme 1,3-β-glucan...

  • Amphotericin B Is Cytotoxic at Locally Delivered Concentrations. Harmsen, Samuel; McLaren, Alex; Pauken, Christine; McLemore, Ryan // Clinical Orthopaedics & Related Research;Nov2011, Vol. 469 Issue 11, p3016 

    Background: Orthopaedic fungal infections are commonly treated with systemic amphotericin, which has a narrow therapeutic index and is associated with systemic toxicities. Local delivery of amphotericin has been described yet is poorly understood. As with bacterial infections, fungal infections...

  • Caspofungin: A Viewpoint by Ben E. De Pauw. de Pauw, B.E. // Drugs;Jun2001, Vol. 61 Issue 8, p1130 

    Evaluates the efficacy of caspofungin in the treatment of fungal infections. Information on amphotericin B and azoles drugs for fungal infections; Drugs that can be combined with caspofungin.

  • Fungal infections are treated. Investor's Business Daily // Investors Business Daily;6/25/2015, pA02 

    The article reports on the treatment of fungal infections with the use of anti-fungals including echinocandins, azoles, and polyenes.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics